Cell therapy, a new therapeutic approach that uses a patient"s own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body"s first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
The global NK Cell Therapy market size was valued at US$ 421 million in 2023 and is forecast to a readjusted size of USD 1164 million by 2030 with a CAGR of 15.8% during review period.
North America is the largest NK Cell Therapy market with about 51% market share. Europe is follower, accounting for about 33% market share.The key manufacturers are Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech etc. Top 3 companies occupied about 82% market share.
This report is a detailed and comprehensive analysis for global NK Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global NK Cell Therapy market size and forecasts, in consumption value ($ Million), 2019-2030
Global NK Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global NK Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global NK Cell Therapy market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for NK Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global NK Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
NK Cell Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
NK Cell Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
NK Cell Therapies
NK Cell Directed Antibodies
麻豆原创 segment by Application
Cancer
Gastrointestinal Diseases
Others
麻豆原创 segment by players, this report covers
Nektar Therapeutics
Innate Pharma SA
Affimed
Chipscreen Biosciences
Fate Therapeutics
Glycostem Therapeutics
Dragonfly Therapeutics
Kiadis Pharma
NantWorks
Nkarta Therapeutics
Fortress Biotech
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe NK Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of NK Cell Therapy, with revenue, gross margin, and global market share of NK Cell Therapy from 2019 to 2024.
Chapter 3, the NK Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and NK Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of NK Cell Therapy.
Chapter 13, to describe NK Cell Therapy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of NK Cell Therapy by Type
1.3.1 Overview: Global NK Cell Therapy 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global NK Cell Therapy Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 NK Cell Therapies
1.3.4 NK Cell Directed Antibodies
1.4 Global NK Cell Therapy 麻豆原创 by Application
1.4.1 Overview: Global NK Cell Therapy 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Cancer
1.4.3 Gastrointestinal Diseases
1.4.4 Others
1.5 Global NK Cell Therapy 麻豆原创 Size & Forecast
1.6 Global NK Cell Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global NK Cell Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global NK Cell Therapy 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America NK Cell Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe NK Cell Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific NK Cell Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America NK Cell Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa NK Cell Therapy 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Nektar Therapeutics
2.1.1 Nektar Therapeutics Details
2.1.2 Nektar Therapeutics Major Business
2.1.3 Nektar Therapeutics NK Cell Therapy Product and Solutions
2.1.4 Nektar Therapeutics NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Nektar Therapeutics Recent Developments and Future Plans
2.2 Innate Pharma SA
2.2.1 Innate Pharma SA Details
2.2.2 Innate Pharma SA Major Business
2.2.3 Innate Pharma SA NK Cell Therapy Product and Solutions
2.2.4 Innate Pharma SA NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Innate Pharma SA Recent Developments and Future Plans
2.3 Affimed
2.3.1 Affimed Details
2.3.2 Affimed Major Business
2.3.3 Affimed NK Cell Therapy Product and Solutions
2.3.4 Affimed NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Affimed Recent Developments and Future Plans
2.4 Chipscreen Biosciences
2.4.1 Chipscreen Biosciences Details
2.4.2 Chipscreen Biosciences Major Business
2.4.3 Chipscreen Biosciences NK Cell Therapy Product and Solutions
2.4.4 Chipscreen Biosciences NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Chipscreen Biosciences Recent Developments and Future Plans
2.5 Fate Therapeutics
2.5.1 Fate Therapeutics Details
2.5.2 Fate Therapeutics Major Business
2.5.3 Fate Therapeutics NK Cell Therapy Product and Solutions
2.5.4 Fate Therapeutics NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Fate Therapeutics Recent Developments and Future Plans
2.6 Glycostem Therapeutics
2.6.1 Glycostem Therapeutics Details
2.6.2 Glycostem Therapeutics Major Business
2.6.3 Glycostem Therapeutics NK Cell Therapy Product and Solutions
2.6.4 Glycostem Therapeutics NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Glycostem Therapeutics Recent Developments and Future Plans
2.7 Dragonfly Therapeutics
2.7.1 Dragonfly Therapeutics Details
2.7.2 Dragonfly Therapeutics Major Business
2.7.3 Dragonfly Therapeutics NK Cell Therapy Product and Solutions
2.7.4 Dragonfly Therapeutics NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Dragonfly Therapeutics Recent Developments and Future Plans
2.8 Kiadis Pharma
2.8.1 Kiadis Pharma Details
2.8.2 Kiadis Pharma Major Business
2.8.3 Kiadis Pharma NK Cell Therapy Product and Solutions
2.8.4 Kiadis Pharma NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Kiadis Pharma Recent Developments and Future Plans
2.9 NantWorks
2.9.1 NantWorks Details
2.9.2 NantWorks Major Business
2.9.3 NantWorks NK Cell Therapy Product and Solutions
2.9.4 NantWorks NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 NantWorks Recent Developments and Future Plans
2.10 Nkarta Therapeutics
2.10.1 Nkarta Therapeutics Details
2.10.2 Nkarta Therapeutics Major Business
2.10.3 Nkarta Therapeutics NK Cell Therapy Product and Solutions
2.10.4 Nkarta Therapeutics NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Nkarta Therapeutics Recent Developments and Future Plans
2.11 Fortress Biotech
2.11.1 Fortress Biotech Details
2.11.2 Fortress Biotech Major Business
2.11.3 Fortress Biotech NK Cell Therapy Product and Solutions
2.11.4 Fortress Biotech NK Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Fortress Biotech Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global NK Cell Therapy Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of NK Cell Therapy by Company Revenue
3.2.2 Top 3 NK Cell Therapy Players 麻豆原创 Share in 2023
3.2.3 Top 6 NK Cell Therapy Players 麻豆原创 Share in 2023
3.3 NK Cell Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 NK Cell Therapy 麻豆原创: Region Footprint
3.3.2 NK Cell Therapy 麻豆原创: Company Product Type Footprint
3.3.3 NK Cell Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global NK Cell Therapy Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global NK Cell Therapy 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global NK Cell Therapy Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global NK Cell Therapy 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America NK Cell Therapy Consumption Value by Type (2019-2030)
6.2 North America NK Cell Therapy 麻豆原创 Size by Application (2019-2030)
6.3 North America NK Cell Therapy 麻豆原创 Size by Country
6.3.1 North America NK Cell Therapy Consumption Value by Country (2019-2030)
6.3.2 United States NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe NK Cell Therapy Consumption Value by Type (2019-2030)
7.2 Europe NK Cell Therapy Consumption Value by Application (2019-2030)
7.3 Europe NK Cell Therapy 麻豆原创 Size by Country
7.3.1 Europe NK Cell Therapy Consumption Value by Country (2019-2030)
7.3.2 Germany NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific NK Cell Therapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific NK Cell Therapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific NK Cell Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific NK Cell Therapy Consumption Value by Region (2019-2030)
8.3.2 China NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America NK Cell Therapy Consumption Value by Type (2019-2030)
9.2 South America NK Cell Therapy Consumption Value by Application (2019-2030)
9.3 South America NK Cell Therapy 麻豆原创 Size by Country
9.3.1 South America NK Cell Therapy Consumption Value by Country (2019-2030)
9.3.2 Brazil NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa NK Cell Therapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa NK Cell Therapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa NK Cell Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa NK Cell Therapy Consumption Value by Country (2019-2030)
10.3.2 Turkey NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE NK Cell Therapy 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 NK Cell Therapy 麻豆原创 Drivers
11.2 NK Cell Therapy 麻豆原创 Restraints
11.3 NK Cell Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 NK Cell Therapy Industry Chain
12.2 NK Cell Therapy Upstream Analysis
12.3 NK Cell Therapy Midstream Analysis
12.4 NK Cell Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Nektar Therapeutics
Innate Pharma SA
Affimed
Chipscreen Biosciences
Fate Therapeutics
Glycostem Therapeutics
Dragonfly Therapeutics
Kiadis Pharma
NantWorks
Nkarta Therapeutics
Fortress Biotech
听
听
*If Applicable.
